Please use this identifier to cite or link to this item: https://scholarhub.balamand.edu.lb/handle/uob/5748
DC FieldValueLanguage
dc.contributor.authorKaram, Lounaen_US
dc.contributor.authorHoushaymi, Bilalen_US
dc.contributor.authorAbdel-Samad, Ranaen_US
dc.contributor.authorJaafar, Mariamen_US
dc.contributor.authorHalloum, Imanen_US
dc.contributor.authorPisano, Claudioen_US
dc.contributor.authorNeipel, Franken_US
dc.contributor.authorDarwiche, Nadineen_US
dc.contributor.authorAbou Merhi, Raghidaen_US
dc.date.accessioned2022-06-09T06:07:34Z-
dc.date.available2022-06-09T06:07:34Z-
dc.date.issued2018-
dc.identifier.issn1021335X-
dc.identifier.urihttps://scholarhub.balamand.edu.lb/handle/uob/5748-
dc.description.abstractPrimary effusion lymphoma (PEL) is a rare B-cell neoplasm, associated with Kaposi sarcoma-associated herpes virus/human herpes virus-8 (KSHV/HHV-8), arising as malignant effusions in body cavities. PEL cells do not harbor conventional genetic cancer mutations; however, their oncogenesis is mainly attributed to HHV-8 latent genes. Treatment strategies are inefficient resulting in poor prognosis of PEL patients, stressing the need for new effective therapy. ST1926 is a synthetic retinoid with favorable antitumor properties and no cross-resistance with the natural retinoid, all-trans retinoic acid. ST1926 has shown potent apoptotic activities on a variety of solid tumors and hematologic malignancies in in vitro and in vivo models. In the present study we elucidated the antitumor activities and underlying molecular mechanism of ST1926 using in vitro, ex vivo, and in vivo PEL preclinical models. ST1926, at sub‑micromolar concentrations, displayed potent antiproliferative effects on PEL cell lines and malignant ascites. Furthermore, ST1926 treatment of PEL cells and ascites resulted in their accumulation in the sub-G1 region, S phase cell cycle arrest, early DNA damage, PARP cleavage and p53 activation including the upregulation of its target genes p21 and Bax. However, ST1926 did not significantly modulate HHV-8 latent viral transcripts. Importantly, ST1926 delayed formation of ascites and enhanced survival of PEL mice. These results highlight the therapeutic potential of ST1926 in combination with drugs that target HHV-8 in PEL patients.en_US
dc.language.isoengen_US
dc.subjectApoptosisen_US
dc.subjectDNA damageen_US
dc.subjectNOD/SCID miceen_US
dc.subjectPrimary effusion lymphomaen_US
dc.subjectST1926en_US
dc.titleAntitumor activity of the synthetic retinoid ST1926 on primary effusion lymphoma in vitro and in vivo modelsen_US
dc.typeJournal Articleen_US
dc.identifier.doi10.3892/or.2017.6137-
dc.identifier.pmid29207182-
dc.identifier.scopus2-s2.0-85038375376-
dc.identifier.urlhttps://api.elsevier.com/content/abstract/scopus_id/85038375376-
dc.contributor.affiliationFaculty of Health Sciencesen_US
dc.description.volume39en_US
dc.description.issue2en_US
dc.description.startpage721en_US
dc.description.endpage730en_US
dc.date.catalogued2022-06-08-
dc.description.statusPublisheden_US
dc.identifier.ezproxyURLhttp://ezsecureaccess.balamand.edu.lb/login?url=https://doi.org/10.3892/or.2017.6137en_US
dc.relation.ispartoftextOncology Reportsen_US
Appears in Collections:Department of Medical Laboratory Sciences
Show simple item record

SCOPUSTM   
Citations

8
checked on Nov 23, 2024

Record view(s)

68
checked on Nov 23, 2024

Google ScholarTM

Check

Altmetric

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.